10-K: Travere Therapeutics Reports Full Year 2023 Results, Advances Pipeline

Travere Therapeutics' 2023 annual report highlights the commercial launch of FILSPARI, progress in clinical trials, and a strategic reorganization.

Summary

• Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases.
• The company achieved accelerated FDA approval for FILSPARI for IgAN in February 2023 and commercially launched the product.
• Topline results from the PROTECT study showed long-term kidney function preservation with FILSPARI, though it narrowly missed statistical significance on one endpoint.
• The company plans to submit a supplemental New Drug Application (sNDA) in the first quarter of 2024 for full approval of FILSPARI.
• The DUPLEX study of sparsentan for FSGS did not achieve its primary endpoint, but the company is exploring potential regulatory pathways.
• The company initiated the pivotal Phase 3 HARMONY Study for pegtibatinase in HCU, with topline results expected in 2026.
• A strategic reorganization in December 2023 included a 20% workforce reduction, expected to save approximately $25 million annually.
• The company sold its bile acid product portfolio to Mirum Pharmaceuticals for $210 million upfront, with potential for up to $235 million in milestone payments.
• The company reported total revenue of $145.2 million for 2023, including $127.5 million in net product sales and $17.7 million in license and collaboration revenue.
• The company had cash and cash equivalents of $58.2 million and marketable debt securities of $508.7 million as of December 31, 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as the commercial launch of FILSPARI and progress in clinical trials, there are also setbacks like the DUPLEX study results and the need for a strategic reorganization. The financial results show a net loss, but the sale of the bile acid business provides a significant cash infusion. Overall, the sentiment is neutral with some positive and negative aspects.

Positives

• FILSPARI's commercial launch is underway and generating revenue.
• The PROTECT study showed long-term kidney function preservation with FILSPARI.
• The company is actively pursuing regulatory pathways for sparsentan in FSGS.
• The Phase 3 HARMONY Study for pegtibatinase is underway.
• The sale of the bile acid portfolio provides a significant cash infusion.
• The strategic reorganization is expected to improve cost structure.

Negatives

• The DUPLEX study of sparsentan for FSGS did not achieve its primary endpoint.
• The PROTECT study narrowly missed statistical significance on one endpoint.
• Thiola sales are impacted by generic competition.
• The company incurred a net loss of $111.4 million for 2023.

Risks

• The continued approval of FILSPARI is contingent upon confirmation of clinical benefit.
• The company may not be able to obtain full approval for FILSPARI or approval for sparsentan in FSGS.
• The company faces competition from generic versions of Thiola and other therapies.
• The company may not be able to achieve or maintain market acceptance for its products.
• The company may need substantial funding and may be unable to raise capital when needed.
• The company is dependent on third parties for manufacturing and distribution.
• The company may not receive some or all of the potential milestone payments from the sale of its bile acid product portfolio.
• The company may be unable to successfully integrate new products or businesses it may acquire.
• The company may become involved in litigation matters, which could result in substantial costs.
• The company is subject to significant ongoing regulatory obligations and oversight.

Future Outlook

The company expects to submit a supplemental New Drug Application (sNDA) for full approval of FILSPARI in the first quarter of 2024 and anticipates an opinion by the CHMP on the conditional marketing authorization (CMA) application for sparsentan for the treatment of IgAN in the EU in the first quarter of 2024. Topline results from the HARMONY Study for pegtibatinase are expected in 2026.

Management Comments

• The company is encouraged by the results of the PROTECT study, including the long-term kidney function preservation.
• The company is continuing to analyze the data from the DUPLEX study to further evaluate the potential for sparsentan as a treatment for FSGS.
• The company is committed to ensuring broad access and educational and diagnostic support for patients.

Industry Context

The document highlights the competitive landscape in the pharmaceutical and biotechnology industries, particularly in the areas of rare kidney and metabolic diseases. It mentions several competitors with programs in clinical development for IgAN and FSGS, including Calliditas, Novartis, Roche, and others. The document also notes the global regulatory label expansions of SGLT2 inhibitors in chronic kidney disease, which could potentially be competitive with or complementary to sparsentan.

Comparison to Industry Standards

• The document mentions several competitors in the IgAN space, including Calliditas, Novartis, Roche, and others, indicating a competitive landscape.
• The company's approach of targeting specific pathways in IgAN with FILSPARI is contrasted with the traditional standard of care, which includes RAAS blockade and immunosuppression.
• The document notes that there are currently no FDA-approved pharmacologic treatments for FSGS, highlighting the unmet need in this area.
• The company's reliance on third-party manufacturers is common in the biopharmaceutical industry, but it also presents risks.
• The company's use of a specialty sales force is typical for rare disease products.

Stakeholder Impact

• Shareholders: The company's stock price may be volatile due to the mixed results and the need for potential future capital raises.
• Employees: The strategic reorganization included a 20% workforce reduction, impacting non-field-based employees.
• Patients: The company is focused on delivering life-changing therapies to patients with rare kidney and metabolic diseases.
• Customers: The company is working to ensure broad access and educational and diagnostic support for patients.

Next Steps

• Submit a supplemental New Drug Application (sNDA) for full approval of FILSPARI in the first quarter of 2024.
• Engage with the EMA to determine the potential for a subsequent variation to the Conditional Marketing Authorization (CMA) of sparsentan for the treatment of FSGS.
• Continue the Phase 3 HARMONY Study for pegtibatinase in HCU.
• Continue to evaluate potential opportunities to expand the pipeline and approved products through licenses and acquisitions.

Key Dates

Keywords

FILSPARI, sparsentan, pegtiabatinase, IgAN, FSGS, HCU, Thiola, kidney disease, metabolic disease, clinical trials, FDA approval, commercialization, biopharmaceutical, orphan drug, proteinuria